全球眼高压治疗市场 – 行业趋势及 2030 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

全球眼高压治疗市场 – 行业趋势及 2030 年预测

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 页面
  • 桌子數: 220
  • 图号: 60

Global Ocular Hypertension Treatment Market

市场规模(十亿美元)

CAGR :  % Diagram

Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 3.00 Billion
Diagram Market Size (Forecast Year)
USD 3.80 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Aerie Pharmaceuticals
  • Abbvie
  • Angelini Pharma
  • Chong Kun Dang pharmaceutical Corp
  • Laboratorios Sophia

全球眼高压治疗市场,按类型(眼高压、青光眼)、给药途径(口服、肠外、其他)、最终用户(医院、专科诊所、其他)、分销渠道(医院药房、零售药房、其他)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房)– 行业趋势和预测到 2030 年。

眼高压治疗市场

眼高压治疗市场分析及规模

根据世界卫生组织 2021 年 10 月关于失明和视力障碍的记录,预计近 22 亿人面临远距离或近距离视力障碍。眼部相关疾病已成为所有中等收入和工业化国家人口的潜在威胁。视力障碍的主要原因包括未矫正的屈光不正、老年性黄斑变性、白内障等。

 Data Bridge Market Research 分析了 2023-2030 年预测期内全球眼高压治疗市场的增长率。在上述预测期内,全球眼高压治疗市场的预期复合年增长率趋于 3% 左右。2022 年市场价值为 51.3 亿美元,到 2030 年将增长至 65 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

眼高压治疗市场范围和细分

报告指标

细节

预测期

2023 至 2030 年

基准年

2022

历史岁月

2021(可定制为 2015 – 2020)

定量单位

收入(百万美元)、销量(单位)、定价(美元)

涵盖的领域

类型(眼压升高、青光眼)、给药途径(口服、肠外、其他)、最终用户(医院、专科诊所、其他)、分销渠道(医院药房、零售药房、其他)、分销渠道(医院药房、网上药房、零售药房)

覆盖国家

北美的美国、加拿大和墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、高血压治疗、土耳其、欧洲其他地区(欧洲)、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区(APAC)其他地区(APAC)、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲(MEA)其他地区(中东和非洲(MEA)的一部分)、巴西、阿根廷和南美洲其他地区(南美洲)

涵盖的市场参与者

Aerie Pharmaceuticals, Inc. (U.S.), Abbvie, Inc (U.S.), Angelini Pharma S.p.a.(Italy), Chong Kun Dang pharmaceutical Corp (South Korea), Laboratorios Sophia (Mexico), Lee Pharma Ltd (Hong Kong), Neurim Pharmaceuticals LTD (Israel), Nicox (France), Novartis AG (Switzerland), Ocular Therapeutix, Inc. (U.S.), Sylentis, S.A (Spain), Taejoon Pharm (South Korea), Takeda Pharmaceutical Company Limited (Japan), Bausch Health Companies Inc. (Canada.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel)

Market Opportunities

  • Rising Strategic Initiatives
  • Increasing R&D Activities

Market Definition

Ocular hypertension happens when the eye's pressure (intraocular pressure or IOP) becomes higher than average. It instigates increased eye strain. Glaucoma may be caused by increased pressure than the normal eye pressure. Glaucoma is a type of condition in which eye pressure affects the optic nerve and leads to loss of vision. However, ocular hypertension is not similar to glaucoma. In this condition, the optic nerve looks normal and there are no signs of vision loss. Although, many people having ocular hypertension are at increased risk for glaucoma and are considered “glaucoma suspects.”

Global Ocular Hypertension Treatment Market Dynamics

Drivers

  • Increase in elderly population

The global ocular hypertension treatment market is projected to witness a heavy growth rate during the forecast period driven by the factor of an aging population. The growing demand in the global ocular hypertension treatment market is the replication of the rising elderly population, as people aged over 60 years normally develop conditions wherein the eyes have reduced elasticity, affecting the normal functioning. This boost the market growth.

  • Advanced technological advancements

Increasing technological advancements associated with the ocular hypertension treatment and diagnostics are boosting the growth of the market. Technologies such as medical imaging, selective laser trabeculoplasty (SLT), visual fields, micro-invasive glaucoma surgery (MIGS), optical coherence tomography (OCT), and progression analysis software will increase patient preference. Moreover, the market size will increase if laser therapies are combined with medications to treat glaucoma as the first-line therapy. This boosts the market growth

Opportunities

  • Rising strategic initiatives

The strategic initiatives that major key players undertake is projected to increase the market growth. For instance, in June 2022, Novartis Pharmaceuticals Corporation announced the acquisition of Kedalion Therapeutics for its novel AcuStream technology. This acquisition pushed Novartis to boost its ophthalmic product portfolio. In addition to this, in June 2022 Amring Pharmaceuticals Inc. announced that its generic Timolol Maleate Ophthalmic Solution has received approval from the U.S FDA. Timolol Maleate Ophthalmic Solution is a preservative-free solution and is recommended in the treatment of open-angle glaucoma and ocular hypertension.

  • Increasing R&D activities

Increasing research and development activities and expenditure by top market players is expected to increase the market growth during the projected period. For an instance, Alcon, a leader in eye care spent USD 842 million on R&D in 2021 as compared to USD 673 million in 2020. Alcon provides an extensive range of products such as contact lenses, cataracts, and glaucoma products. Thus, all these increasing healthcare expenditures create many market growth opportunities.

 Restraints/Challenges

  • Lack of skilled professionals

The lack of skilled healthcare professionals who are unable to treat the patients with appropriate treatments could restrain the growth of the global ocular hypertension treatment market over a forecast period.

  • High cost

The huge expenditure associated with the treatment of ocular hypertension hamper the market growth. The treatment involves various types of surgery and costly diagnostic procedures that somewhat hinder the market growth.

This global ocular hypertension treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global ocular hypertension treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Ocular Hypertension Treatment Market           

The Covid-19 pandemic significantly affected the market due to a reduction in number of patient visits in hospitals and clinics for ocular disorders and interruption of numerous alternative procedures and outpatient visits. For instance, as per the records of Clinical Ophthalmology Journal, in November 2021, in the analysis of post-pandemic and pre-pandemic data, it can be expected that visual field checkups, medications released, clinical visits, and surgical procedures declined 93.84%, 19.63%, ,92.52%, and 72.74% at the time when pre and post-pandemic times were compared. Thus, the data tells that the treatment of glaucoma and other ophthalmic disorders reduced considerably. Though, the market is projected to witness a spike due to the wide availability of COVID-19 vaccines and decreasing COVID-19 cases.

Global Ocular Hypertension Treatment Market Scope

The global ocular hypertension treatment market is segmented on the basis of type, route of administration , drug type, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Intraocular Hypertension
  • Glaucoma

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Type

  • Prescription
  • Over the Counter

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Ocular Hypertension Treatment Market Regional Analysis/Insights

The global ocular hypertension treatment market is analyzed and market size insights and trends are provided by type, route of administration, drug type, distribution channel and end-user as referenced above.

The major countries covered in the global ocular hypertension treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Shypertension treatment, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global ocular hypertension treatment market throughout the forecasted period due to the highest number of geriatric and vulnerable populations.

North America dominates the market due to the increase in research & development activities for the development of novel therapies.

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外,在提供国家数据预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球眼高压治疗市场份额分析

全球眼高压治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球眼高压治疗市场的关注有关。

全球眼高压治疗市场的主要参与者包括:

  • Aerie Pharmaceuticals, Inc.(美国)
  • Abbvie, Inc(美国)
  • Angelini Pharma Spa(意大利)
  • 郑根堂制药公司 (韩国)
  • Laboratorios Sophia(墨西哥)
  • 李氏大药厂有限公司 (香港)
  • Neurim Pharmaceuticals LTD(以色列)
  • Nicox(法国)
  • 诺华公司(瑞士)
  • Ocular Therapeutix, Inc.(美国)
  • Sylentis, SA(西班牙)
  • Taejoon Pharm(韩国)
  • 武田药品工业株式会社 (日本)
  • Bausch Health Companies Inc.(加拿大),
  • 默克公司(美国)
  • 辉瑞公司(美国)
  • Teva Pharmaceutical Industries Ltd.(以色列)

研究方法:全球眼高压治疗市场     

数据收集和基准年分析是使用具有大样本量的数据收集模块进行的。市场数据使用市场统计和连贯模型进行分析和估计。市场份额分析和关键趋势分析也是市场报告中的主要成功因素。如需了解更多信息,请请求分析师致电或下拉询问。

DBMR 研究团队使用的关键研究方法是数据三角测量,涉及数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们很自豪能够为现有和新客户提供符合其目标的数据和分析。报告可以定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(Factbook)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The market is segmented based on , By Type (Intraocular Hypertension, Glaucoma), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
The Global Ocular Hypertension Treatment Market size was valued at USD 3.00 USD Billion in 2022.
The Global Ocular Hypertension Treatment Market is projected to grow at a CAGR of 3% during the forecast period of 2023 to 2030.
The major players operating in the market include Aerie Pharmaceuticals, Abbvie, Angelini Pharma, Chong Kun Dang pharmaceutical Corp, Laboratorios Sophia, Lee Pharma Ltd, Neurim Pharmaceuticals LTD, Nicox, Novartis AG, Ocular Therapeutix, Sylentis, Taejoon Pharm, Takeda Pharmaceutical Company Limited, Bausch Health Companies , Merck & Co. , Pfizer , Teva Pharmaceutical Industries .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Shypertension treatment, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.